{"disease":{"id":"lipoproteinemia","name":"lipoproteinemia"},"drugs":{"marketed":[{"drug_id":"atorvastatin","indication_name":"Familial type 3 hyperlipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"atorvastatin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":77,"revenue":"1000.0","mechanism":"Selective competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis."},{"drug_id":"caduet","indication_name":"Primary Dysbetalipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caduet","generic_name":"Amlodipine Besylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channel","drug_class":"Dihydropyridine calcium channel blocker","quality_score":76,"revenue":null,"mechanism":"Calcium channel antagonist inhibiting transmembrane calcium influx into vascular and cardiac muscle."},{"drug_id":"inositol","indication_name":"Hypoalphalipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inosital","generic_name":"INOSITOL","company_name":"","drug_phase":"discontinued","molecular_target":"","drug_class":"inositol","quality_score":null,"revenue":null,"mechanism":"Inosital works by influencing the metabolism of lipids in the body."},{"drug_id":"simvastatin","indication_name":"Familial type 3 hyperlipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zocor","generic_name":"simvastatin","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"simvastatin","indication_name":"Hypoalphalipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zocor","generic_name":"simvastatin","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"acipimox","indication_name":"Hyperlipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Olbemox","generic_name":"ACIPIMOX","company_name":"","drug_phase":"phase_3","molecular_target":"Hydroxycarboxylic acid receptor 2","drug_class":"acipimox","quality_score":null,"revenue":null,"mechanism":"Olbemox works by activating the hydroxycarboxylic acid receptor 2, which helps to reduce the production of triglycerides in the liver."},{"drug_id":"myoinositol","indication_name":"Hypoalphalipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Myoinositol","company_name":"University of Colorado, Denver","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"fenofibrate","indication_name":"Hypoalphalipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tricor (Micronized)","generic_name":"FENOFIBRATE","company_name":"Salix","drug_phase":"marketed","molecular_target":"PPARα","drug_class":"Peroxisome Proliferator Receptor alpha Agonist [EPC]","quality_score":80,"revenue":null,"mechanism":"Fenofibrate activates PPARα, enhancing lipolysis and reducing triglycerides, while increasing HDL-cholesterol and uric acid excretion."},{"drug_id":"rosuvastatin","indication_name":"Familial type 3 hyperlipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Crestor","generic_name":"rosuvastatin","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":74,"revenue":null,"mechanism":"Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate, a cholesterol precursor."},{"drug_id":"lipitor","indication_name":"Familial type 3 hyperlipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"Atorvastatin Calcium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"atorvastatin","quality_score":10,"revenue":null,"mechanism":"Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, a key enzyme in cholesterol synthesis."},{"drug_id":"choline-fenofibrate","indication_name":"Hypoalphalipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trilipix","generic_name":"CHOLINE FENOFIBRATE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Fatty acid-binding protein, intestinal","drug_class":"Peroxisome Proliferator Receptor alpha Agonist","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"lovastatin","indication_name":"Hypoalphalipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mevacor","generic_name":"LOVASTATIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":null,"revenue":null,"mechanism":"Mevacor works by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol production in the liver."},{"drug_id":"chembl-chembl1496","indication_name":"Treat primary dysbetalipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ROSUVASTATIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"olbetam","indication_name":"Hyperlipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olbetam","company_name":"University of Aarhus","drug_phase":"phase_1","molecular_target":"Hydroxycarboxylic acid receptor 2","drug_class":"","quality_score":4,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":14,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06304415","title":"Elevated Lipoprotein(a) in Hospital Staff","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2800,"lead_sponsor_name":"Changi General Hospital","has_results":false},{"nct_id":"NCT03110432","title":"Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry","phase":"","overall_status":"COMPLETED","enrollment_count":1695,"lead_sponsor_name":"GWT-TUD GmbH","has_results":false},{"nct_id":"NCT03549637","title":"Prevalence of fAmilial hypobetalipopRoTeinemIa in psychiaTrIc pOpulatioN (PARTITION)","phase":"NA","overall_status":"COMPLETED","enrollment_count":896,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT00001154","title":"Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins","phase":"","overall_status":"COMPLETED","enrollment_count":759,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT00552097","title":"Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE)(P02578)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":720,"lead_sponsor_name":"Organon and Co","has_results":false},{"nct_id":"NCT05181969","title":"Long-term Characterization of Lipoprotein Apheresis Technologies for Individual Device Adaption (LOLIDA)","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Technische Universität Dresden","has_results":false},{"nct_id":"NCT02354079","title":"HYPOCHOL : A Genetically-based Strategy to Identify New Targets in Cholesterol Metabolism","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":435,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT05425745","title":"Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":354,"lead_sponsor_name":"NewAmsterdam Pharma","has_results":true},{"nct_id":"NCT01524289","title":"Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":306,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04516291","title":"A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":286,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06439654","title":"Atlantic Lipid Lowering Treatment Optimization Program","phase":"NA","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Atlantic Health System","has_results":false},{"nct_id":"NCT05256654","title":"A Study of LY3561774 in Participants With Mixed Dyslipidemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":205,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT06526013","title":"Cholesterol Self-testing in Patients Post Acute Coronary Syndrome","phase":"NA","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"University of Leipzig","has_results":false},{"nct_id":"NCT04330209","title":"Comparing a Low-GI Nutrigenetic and Ketogenic Diet for Weight Loss With 18 Month Follow-up","phase":"","overall_status":"COMPLETED","enrollment_count":114,"lead_sponsor_name":"Iuliu Hatieganu University of Medicine and Pharmacy","has_results":false},{"nct_id":"NCT05661552","title":"Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":108,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT07405814","title":"Clinical Trial On The Effect Of Artisterol On Risk Factors In Individuals With Suboptimal Cholesterol Levels","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":106,"lead_sponsor_name":"Zentiva, k.s.","has_results":false},{"nct_id":"NCT03109834","title":"Effect of Weight Management Programs on Cardiometabolic Risk Profile in Overweight Women","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"Bonn Education Association for Dietetics r.A., Cologne, Germany","has_results":false},{"nct_id":"NCT06154408","title":"Evaluating the Impact of Omega-3 Fatty Acid Supplementation (Soloways™) on Lipid Profiles in Adults With PPARG Polymorphisms","phase":"NA","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"S.LAB (SOLOWAYS)","has_results":false},{"nct_id":"NCT04897113","title":"Study of Efficacy and Safety of the Plasmapheresis Method With Albumin Compensation Compared With the Plasmapheresis Method Without Albumin Compensation for Aging Biomarkers Correction in Men and Women Aged 40 to 55 Years Old","phase":"NA","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"National Medical Research Center for Rehabilitation and Balneology","has_results":false},{"nct_id":"NCT04613167","title":"Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and Treatment","phase":"NA","overall_status":"UNKNOWN","enrollment_count":70,"lead_sponsor_name":"University Medical Centre Ljubljana","has_results":false},{"nct_id":"NCT02658175","title":"The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Akcea Therapeutics","has_results":true},{"nct_id":"NCT04261803","title":"FH Detection in Children by Salivary Test","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT06163443","title":"Evaluating the Impact of B Vitamin Supplementation (Soloways™) on Homocysteine and LDL-C Levels in Patients With MTHFR, MTR, and MTRR Polymorphisms.","phase":"NA","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"S.LAB (SOLOWAYS)","has_results":false},{"nct_id":"NCT05305664","title":"A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06420817","title":"Effect of a Customised Lifestyle Medicine Strategy on Lowering Blood Lipid Levels in Indian Physicians","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Jubilee Mission Medical College and Research Institute","has_results":false},{"nct_id":"NCT05900141","title":"An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":41,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03607383","title":"Red Rice Yeast in Low-density Lipoprotein (LDL) Lowering: an Efficacy Study","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Saint-Joseph University","has_results":false},{"nct_id":"NCT07157878","title":"Gingival Crevicular Fluid Oxidized Low-Density Lipoprotein Levels in Health and Stage III/IV Periodontitis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"shaimaa hamdy","has_results":false},{"nct_id":"NCT06333158","title":"Extracts of Amla, Walnut Leaf, Red Yeast Rice and Olive in Cardiovascular Prevention","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Nina Hermans","has_results":false},{"nct_id":"NCT04247048","title":"Kinetic Study of Lp(a) and PCSK9 in Humans","phase":"NA","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT05569928","title":"In Vivo Metabolism of apoB-containing Lipoproteins in ANGPTL3 Deficient Subjects","phase":"NA","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Marcello Arca","has_results":false},{"nct_id":"NCT05208879","title":"CArotenoid in hypoChOlesterolemia","phase":"","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT03360747","title":"Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Akcea Therapeutics","has_results":true},{"nct_id":"NCT04993664","title":"Influence of Pelacarsen on Patients After Myocardial Infarction With High Lp(a) Values (PEMILA)","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University Medical Centre Ljubljana","has_results":false},{"nct_id":"NCT06500598","title":"Compassionate Use of Evinacumab","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false}],"total":35},"guidelines":[],"source":"Drug Landscape verified database"}